Metlinka (Metformin Hydrochloride, Sitagliptin)

Metformin reduces hepatic glucose production and increases insulin sensitivity in muscle and fat tissue. Sitagliptin blocks the enzyme DPP‑4, which prolongs the activity of incretin hormones (GLP‑1 and GIP). Together they lower fasting and post‑prandial glucose by enhancing insulin release and suppressing glucagon.

The specific dose of Metlinka is individualized by the prescribing healthcare professional based on the patient’s glycaemic profile, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for Metlinka in pregnancy and lactation are limited. Generally, metformin may be continued if benefits outweigh risks, while sitagliptin is not recommended during pregnancy. Breastfeeding mothers should consult their physician, as the drug may pass into milk.

To request Metlinka, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metlinka offers a dual mechanism—biguanide action of metformin plus DPP‑4 inhibition of sitagliptin—in a single tablet, which can simplify regimens compared with taking separate agents. Unlike sulfonylureas, it carries a lower intrinsic risk of hypoglycaemia, and unlike GLP‑1 receptor agonists, it is an oral formulation.

Metlinka tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, direct sunlight and excessive heat to maintain stability throughout the shelf‑life.

Metlinka is taken orally, usually with a meal to reduce gastrointestinal discomfort. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed by a healthcare professional.

The most serious adverse events include lactic acidosis (particularly in patients with renal impairment), severe hypoglycaemia when combined with insulin or sulfonylureas, acute pancreatitis, and rare allergic reactions such as anaphylaxis. Prompt medical attention is required if any of these occur.

Metlinka is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, and in those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease or uncontrolled heart failure.